Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age

Journal of Hypertension

Volumn 28, Issue 5, 2010, Pages 1083-1090

  Schaefer, Franz ^a   Van De Walle, Johan ^b   Zurowska, Aleksandra ^c   Gimpel, Charlotte ^a   Van Hoeck, Koen ^d   Drozdz, Dorota ^e   Montini, Giovanni ^f   Bagdasorova, Ingretta V ^g   Sorof, Jonathan ^h   Sugg, Jennifer ^h   Teng, Renli ^h   Hainer, James W ^h  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g City of Children Clinical Hospital #7   (Ukraine)

^h ASTRAZENECA   (United Kingdom)

Author keywords

Candesartan cilexetil; Pediatric hypertension; Pediatric renal disease

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CREATININE; PLACEBO; THIAZIDE DIURETIC AGENT;

ABDOMINAL PAIN; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FATIGUE; FEMALE; FOLLOW UP; GASTROENTERITIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LABORATORY TEST; LIQUID; LONG TERM CARE; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MICROALBUMINURIA; MULTICENTER STUDY; PLASMA CONCENTRATION-TIME CURVE; POTASSIUM BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 77951286540     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328336b86b     Document Type: Article

References (23)

1. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. National Institute of Health; National Heart, Lung, and Blood Institute; 2005. pp. 1-48.
2. Flynn JT. Pediatric hypertension: recent trends and accomplishment, future challenges. Am J Hypertens 2008; 21:605-612.
3. Benjamin DK, Smith PB, Jadhav P, Gobburu JV, Murphy MD, Hasselblad V, et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension 2008; 51:834-840. (Pubitemid 351654692)
4. Trachtman H, Frank R, Mahan JD, Portman R, Restaino I, Matoo TK, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol 2003; 18:548-553. (Pubitemid 36790096)
5. Li JS, Berezny K, Kilaru R, Hazan L, Portman R, Hogg R, et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension 2004; 44:289-293. (Pubitemid 39167224)
6. Chandar J, Abitbol C, Montane B, Zilleruelo G. Angiotensin blockade as sole treatment for proteinuric kidney disease in children. Nephrol Dial Transplant 2007; 22:1332-1337. (Pubitemid 47072220)
7. Nakanishi K, Iijima K, Ishikura K, Hataya H, Awazu M, Sako M, et al. Efficacy and safety of lisinopril for mild childhood IgA nephropathy: pilot study. Pediatr Nephrol 2009; 24:845-849.
8. Blowey DL. Approach to the pharmacologic treatment of pediatric hypertension. In: Portman RJ, Sorof JM, Ingelfinger JR, editors. Pediatric hypertension. Totowa, New Jersey, USA: Humana Press; 2004. pp. 429-442.
9. Morsing P, Adler G, Brandt-Eliasson U, Karp L, Ohlson K, Renberg L, et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999; 33:1406-1413. (Pubitemid 29282662)
10. Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effects of four AT-1 receptor blockers. Differences in potency and efficacy. Blood Press 2002; 11:293-301. (Pubitemid 35355844)
11. Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children ages 6-17 years. J Clin Hypertens 2008; 10:743-750.
12. Chevalier RL. Developmental renal physiology of the low birth weight preterm newborn. J Urol 1996; 156:714-719. (Pubitemid 126444910)
13. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, et al. Centers for Disease Control and Prevention 2000 Growth Charts for the United States: improvements to the 1997 National Center for Health Statistics version. Paediatrics 2002; 109:45-60. (Pubitemid 34049426)
14. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20:629-637.
15. Stenhoff H, Lagerstrom PO, Andersen C. Determination of candesartan cilexetil, candesartan and a metabolite in human plasma and urine by liquid chromatography and fluorometric detection. J Chromatogr B 1999; 73:411-417. (Pubitemid 29397610)
16. Flynn JT, Meyers KEC, Neto JP, de Paula Meneses R, Zurowska A, Bagga A, et al. Efficacy and safety of the angiotensin receptor blocking agent valsartan in children with hypertension aged 1 to 5 years. Hypertension 2008; 52:222-228.
17. Wingen AM, Fabian-Bach C, Schaefer F, Mehls O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 1997; 349:1117-1123. (Pubitemid 27168544)
18. Wühl E, Schaefer F. Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol 2008; 23:705-716.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
20. Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 2009; 27:1719-1742.
21. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005; 16:3038-3045. (Pubitemid 44743501)
22. Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S, SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20:893-900.
23. Wühl E, Trivelli A, Matteucci MC, Litwin M, Peco-Antic A, Zurowska A, et al., ESCAPETrial Group. Intensified blood pressure control and progression of chronic renal insufficiency in children. N Engl J Med 2009; 361:1639-1650.